A study investigating the effect of CYP2C19 polymorphism on the therapeutic efficacy in patients with eosinophilic esophagitis

A study investigating the effect of CYP2C19 polymorphism on the therapeutic efficacy in patients with eosinophilic esophagitis - CYP2C19 polymorphism in patients with eosinophilic esophagitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026704

Enrollment

150

Registered

2017-03-27

Start date

2017-03-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic esophagitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who are diagnosed with eosinophilic esophagitis at our hospital 2) Patients who are obtained informed consent prior the study

Exclusion criteria

Exclusion criteria: 1) Patients who are not treated by proton pump inhibitor or those who are not scheduled to treat by proton pump inhibitor 2) Patients who are judged inadequate for this study

Design outcomes

Primary

Measure	Time frame
presence or absence of improvement of eosinophilic infiltration 2 month after administration of proton pump inhibitor	—

Countries

Japan

Contacts

Public ContactNorihisa Ishimura

Shimane University School of Medicine Department of Internal Medicine II

ishimura@med.shimane-u.ac.jp0853-20-2190

Outcome results